Trial · NCT07904845
A Study of BON-C1393 in Adults With Advanced Solid Tumors
NCT07904845, Phase 1, Not yet recruiting, BeOne Medicines
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of BON-C1393 in Adults With Advanced Solid Tumors. Trials, record NCT07904845. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07904845
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of BON-C1393 in Adults With Advanced Solid Tumors
- NCT number
- NCT07904845
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 90 participants, estimated
- Lead sponsor
- BeOne Medicines
- Conditions
- Solid Tumors, Advanced Solid Tumors
- Interventions
- BON-C1393, Bevacizumab, Capecitabine
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase 1a: Number of Participants with Dose-Limiting Toxicities (DLTs) | Approximately 1 month | |
| Primary | Phase 1a: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs) | Up to approximately 9 months | |
| Primary | Phase 1b: Overall Response Rate (ORR) Assessed by the Investigator | Up to approximately 12 months | ORR is defined as the percentage of participants with a best overall response of partial response or better per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
| Secondary | Phase 1a: Overall Response Rate (ORR) Assessed by the Investigator | Up to approximately 9 months | ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
| Secondary | Phase 1a: Duration of Response (DOR) Assessed by the Investigator | Up to approximately 9 months | DOR is defined as the time from the first determination of an objective response until the first documentation of disease progression or death due to any cause, whichever occurs first. |
| Secondary | Phase 1b: Duration of Response (DOR) Assessed by the Investigator | Up to approximately 12 months | DOR is defined as the time from the first determination of an objective response until the first documentation of disease progression or death due to any cause, whichever occurs first. |
| Secondary | Phase 1a: Disease Control Rate (DCR) Assessed by the Investigator | Up to approximately 9 months | DCR is defined as the percentage of participants with a BOR of a CR, PR, or stable disease (SD) per RECIST v1.1. |
| Secondary | Phase 1b: Disease Control Rate (DCR) at 12 Weeks Assessed by the Investigator | 12 Weeks | DCR at 12 weeks is defined as the percentage of participants with CR, PR, or SD per RECIST v1.1, and are alive and progression-free at Week 12. |
| Secondary | Phase 1b: Disease Control Rate (DCR) at 24 Weeks Assessed by the Investigator | 24 weeks | DCR at 24 weeks is defined as the percentage of participants with CR, PR, or SD according to RECIST v1.1, and are alive and progression-free at the Week 24. |
| Secondary | Phase 1b: Progression-free Survival (PFS) Assessed by the Investigator | Up to approximately 12 months | PFS is defined as the time from the date of the first administration of study drug to the date of the first documentation of disease progression or death due to any cause, whichever occurs first. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07904845
GET https://conductscience.org/api/trials/v1/NCT07904845/registered